A carregar...
BRAF inhibitors in clinical oncology
Activating mutations of the BRAF oncogene are present in approximately 5-10% of all human malignancies and lead to constitutive activation of the mitogen activated protein kinase (MAPK) pathway. The introduction of BRAF inhibitors has greatly improved the short term prospects of some patients with t...
Na minha lista:
| Main Authors: | , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Faculty of 1000 Ltd
2013
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3619157/ https://ncbi.nlm.nih.gov/pubmed/23585929 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.12703/P5-11 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|